- Home
- CNSP vs BDRX Comparison
CNSP vs BDRX Comparison
Compare CNSP & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNSP | BDRX |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1M | 1.8M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CNSP | BDRX |
|---|---|---|
| Price | $2.26 | $0.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 29.5K | ★ 100.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.76 |
| 52 Week High | $10.59 | $11.88 |
Technical Indicators
Market Signals| Indicator | CNSP | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 26.57 | 26.38 |
| Support Level | $0.77 | N/A |
| Resistance Level | $4.00 | $1.29 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 9.65 | 1.37 |
Price Performance
Historical ComparisonAbout CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.